Uceris Launched for Ulcerative Colitis
Santarus announced the launch of Uceris (budesonide) extended-release tablets for the induction of remission in patients with active, mild to moderate ulcerative colitis.
Uceris contains budesonide in a novel oral tablet formulation that utilizes proprietary MMX multi-matrix system technology, which is designed to result in the controlled release and distribution of budesonide throughout the length of the colon. Budesonide is a corticosteroid known to have localized anti-inflammatory effect.
Uceris is available in 9mg extended-release tablets in 30-count bottles.For more information call (888) 778-0887 or visit www.uceris.com